Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy InMed Pharmaceuticals stock

Learn how to easily invest in InMed Pharmaceuticals stock.

InMed Pharmaceuticals is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars. InMed Pharmaceuticals employs 13 staff and has a trailing 12-month revenue of around $1.4 million.

How to buy InMed Pharmaceuticals stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – INM. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

InMed Pharmaceuticals stock price (NASDAQ: INM)

Use our graph to track the performance of INM stocks over time.

InMed Pharmaceuticals shares at a glance

Information last updated 2023-02-02.
Latest market close$2.08
52-week range$1.23 - $35.50
50-day moving average $2.06
200-day moving average $9.05
Wall St. target price$20.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.17

Buy InMed Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy InMed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InMed Pharmaceuticals price performance over time

Historical closes compared with the close of $2.08 from 2023-02-02

1 week (2023-01-27) 15.56%
1 month (2023-01-03) -5.88%
3 months (2022-11-03) -26.24%
6 months (2022-08-03) 420.00%
1 year (2022-02-03) 85.71%
2 years (2021-02-03) -60.23%
3 years (2020-01-30) N/A
5 years (2018-02-02) 182.65%

InMed Pharmaceuticals financials

Revenue TTM $1.4 million
Gross profit TTM $543,546
Return on assets TTM -55.54%
Return on equity TTM -145.93%
Profit margin 0%
Book value $12.11
Market capitalisation $3.3 million

TTM: trailing 12 months

InMed Pharmaceuticals share dividends

We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Have InMed Pharmaceuticals's shares ever split?

InMed Pharmaceuticals's shares were split on a 1:25 basis on 7 September 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.

InMed Pharmaceuticals share price volatility

Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $1.23 up to $35.5. A popular way to gauge a stock's volatility is its "beta".

INM.US volatility(beta: 0.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 0.9812. This would suggest that InMed Pharmaceuticals's shares are less volatile than average (for this exchange).

To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.

InMed Pharmaceuticals overview

InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa.

Frequently asked questions

What percentage of InMed Pharmaceuticals is owned by insiders or institutions?
Currently 0.468% of InMed Pharmaceuticals shares are held by insiders and 20.964% by institutions.
How many people work for InMed Pharmaceuticals?
Latest data suggests 13 work at InMed Pharmaceuticals.
When does the fiscal year end for InMed Pharmaceuticals?
InMed Pharmaceuticals's fiscal year ends in June.
Where is InMed Pharmaceuticals based?
InMed Pharmaceuticals's address is: 815 West Hastings Street, Vancouver, BC, Canada, V6C 1B4
What is InMed Pharmaceuticals's ISIN number?
InMed Pharmaceuticals's international securities identification number is: CA4576375022

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site